Cargando…

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis

Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface marker CD3 and malignant cell markers, including B-cell maturation antigen (BCMA), FcRH5, and G protein–coupled receptor GPRC5D. These bispecific antibodies so e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reynolds, Gemma, Cliff, Edward R. Scheffer, Mohyuddin, Ghulam Rehman, Popat, Rakesh, Midha, Shonali, Liet Hing, Melissa Ng, Harrison, Simon J., Kesselheim, Aaron S., Teh, Benjamin W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558589/ https://www.ncbi.nlm.nih.gov/pubmed/37467036 http://dx.doi.org/10.1182/bloodadvances.2023010539

Ejemplares similares

P1518: INFECTIONS FOLLOWING BISPECIFIC ANTIBODIES IN MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Reynolds, Gemma, et al.
Publicado: (2023)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2023)

Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma
por: Najjar, Mimi, et al.
Publicado: (2023)

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020
por: Van Oekelen, Oliver, et al.
Publicado: (2022)

Infectious complications of bispecific antibody therapy in patients with multiple myeloma
por: Sim, Beatrice Z., et al.
Publicado: (2023)

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2021)

National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Hospitalization at the end of life in patients with multiple myeloma
por: Abbasi, Saqib, et al.
Publicado: (2021)

Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Disseminated Invasive Mucormycosis Infection Following Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2016)

A Rare Presentation of a Rare Disease: Pulmonary Lymphomatoid Granulomatosis
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2012)

The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review
por: Khanam, Razwana, et al.
Publicado: (2023)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

A Rare Cause of Hemophagocytic Lymphohistiocytosis: Fusobacterium Infection—A Case Report and Review of the Literature
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2016)

Selinexor: Targeting a novel pathway in multiple myeloma
por: Mo, Clifton C., et al.
Publicado: (2023)

Applying the Principles of Bloom’s Taxonomy to Managing Tachyarrhythmia: Results of a Tachyarrhythmia Workshop
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2019)

Does Use of High-fidelity Simulation Improve Resident Physician Competency and Comfort Identifying and Managing Bradyarrhythmias?
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2020)

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
por: Cho, Shih-Feng, et al.
Publicado: (2022)

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
por: Fatoki, Raleigh Ayoolu, et al.
Publicado: (2022)

Reducing Resident Physician Workload to Improve Well Being
por: Al-kofahi, Mejalli, et al.
Publicado: (2019)

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
por: Abdallah, Al‐Ola, et al.
Publicado: (2021)

Comparison of inconclusive rates between suction rectal biopsy and open strip rectal biopsy in children of different age groups: a single-center retrospective study
por: Ng Liet Hing, Cedric Ian, et al.
Publicado: (2020)

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma
por: Gil, Kellen, et al.
Publicado: (2022)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
por: Swan, Dawn, et al.
Publicado: (2023)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
por: Hosny, Mashhour, et al.
Publicado: (2021)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
por: Wu, Lijun, et al.
Publicado: (2022)

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
por: Hammons, Lindsay R., et al.
Publicado: (2022)

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
por: O'Neill, Chloe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lqhldbv5853914khcen92nv001